InstalabTotal + Free PSA
Should you take a Total + Free PSA test?
This test is most useful if any of these apply to you.
3 Biomarkers Included
- Total PSAMeasures the total prostate-specific antigen (PSA) in your blood. It rises with prostate cancer, but also with benign enlargement, infection, or recent activity, so it flags risk without explaining the cause.A higher total, especially between 4 and 10, signals a need to look closer rather than a diagnosis on its own.
- Free PSAMeasures the share of PSA circulating unbound to other proteins. Cancer tends to keep more PSA bound, so a low free amount shifts the odds toward cancer over benign causes.A low free PSA alongside an elevated total leans the picture toward cancer rather than benign enlargement.
- Free PSA RatioDivides free PSA by total PSA to show what fraction circulates free. This ratio is the panel's sharpest signal for separating cancer from a benign prostate when total PSA is borderline.A lower ratio means higher cancer probability; a higher ratio points toward a benign enlarged prostate.
About Total + Free PSA
A prostate-specific antigen test (PSA, a protein your prostate makes) hands you a single number. That number climbs with prostate cancer, but it also climbs with a harmlessly enlarged prostate, a low-grade infection, or even a long bike ride. On its own, it sends many men toward a biopsy they did not need.
This panel breaks that one number apart. It measures how much PSA is in your blood, how much of it floats free and unbound, and the ratio between the two. Read together, they hint at whether a raised reading leans toward cancer or toward something benign, before you commit to the next step.
What This Panel Reveals
Total PSA answers a blunt question: how much of the protein is circulating? The trouble is that both cancer and benign enlargement (called benign prostatic hyperplasia, or BPH) push it up, and they overlap most in the range of 4 to 10 nanograms per milliliter (ng/mL), a stretch often called the gray zone. Inside that zone, the total alone barely distinguishes the two, and roughly 30 to 35% of men with a PSA here turn out to have cancer on biopsy.
Free PSA and the ratio reveal the missing detail: the form the protein takes. PSA made by cancer cells tends to stay bound to other proteins, so a smaller share circulates free. Benign tissue leaves relatively more of it free. A lower free ratio therefore leans toward cancer, while a higher ratio leans toward a benign gland.
That is the point of running all three together. Two men with an identical total PSA can carry very different risk, and the ratio is what pulls them apart. Long-standing and newer evidence agree on the direction, even if the exact cutoff varies by lab and population.
How to Read Your Results Together
The pattern that matters is the total and the ratio side by side. As a rough guide from biopsy studies, a free ratio of 10% or below has been linked to roughly a 56% chance of cancer on biopsy, while a ratio above 25% dropped that chance to about 8%.
| Your Pattern | What It May Suggest |
|---|---|
| Total PSA 4 to 10, ratio above 25% | Leans toward a benign enlarged prostate; cancer is less likely, though not ruled out. |
| Total PSA 4 to 10, ratio below 15% | Higher cancer likelihood; a urologist visit and prostate imaging are reasonable next steps. |
| Total PSA below 4, low ratio | Can still carry meaningful risk; a low ratio has been tied to more aggressive cancer even here. |
| Total PSA above 10 | Cancer likelihood is already high (above 67%); the ratio adds little, and a fuller workup is usually warranted. |
One caution: interpret the ratio against your own total PSA, not a fixed line. The free share naturally falls as total PSA rises and drifts higher with age and a larger prostate.
What to Do with Your Results
A low ratio shifts probability; it does not diagnose. If your total sits in the gray zone with a low ratio, the sensible path is to repeat the panel under the same conditions, then talk with a urologist. Most will order a prostate MRI (magnetic resonance imaging, a detailed scan) before recommending a biopsy.
Treat this panel as a first, inexpensive refinement rather than the final word. Newer tools, including the Prostate Health Index (a blood score known as PHI) and MRI-guided pathways, generally detect aggressive cancer more accurately and spare more men an unnecessary biopsy. In fact, current guidelines list percent-free PSA mainly as an option after an initial negative biopsy rather than as a preferred test before a first biopsy, where PHI and similar newer markers are favored. For tracking over time, men with low or borderline total PSA can reasonably retest every 2 to 4 years, and only a change beyond about 15 to 20% is likely to mean something real.
When Results Can Be Misleading
Several things move the whole panel at once. Recent ejaculation, a digital rectal exam (a physical prostate check, or DRE), prostate inflammation, and vigorous cycling can all lift PSA for days. The drugs finasteride and dutasteride roughly halve total PSA, which can make a reading look reassuring when it is not.
Sample handling matters too. Free PSA is less stable than total PSA and starts to break down if the blood sits too long before the lab separates it, which can nudge the ratio downward. Drawing all three from one sample and processing it promptly keeps the numbers honest.